Achieving high mass-throughput of therapeutic proteins through parvovirus retentive filters

Biotechnology Progress

Volumn 26, Issue 6, 2010, Pages 1671-1677

  Bolton, Glen R ^a   Basha, Jonida ^a   LaCasse, Daniel P ^a  

^a Purification Process Development   (United States)

Author keywords

Monoclonal antibody; Parvovirus; Throughput; Viral clearance; Virus filtration

Indexed keywords

BUFFER COMPOSITION; COST SAVING; DIATOMACEOUS EARTH; FILTER PLUGGING; FILTRATION AREA; HIGH THROUGHPUT; MANUFACTURING COST; MILLIPORE; OPTIMUM TEMPERATURE; PARVOVIRUS; PREFILTERS; PROTEIN CONCENTRATIONS; SCALE FILTER; SOLUTION PH; THERAPEUTIC PROTEIN; VIRAL CLEARANCE; VIRUS-LIKE PARTICLES; VOLUMETRIC THROUGHPUT;

MONOCLONAL ANTIBODIES; OPTIMIZATION; PROTEINS; SURFACE PLASMON RESONANCE; VIRUSES;

THROUGHPUT;

IMMUNOGLOBULIN G;

ARTICLE; CHEMISTRY; FILTRATION; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR WEIGHT; PARVOVIRUS; TEMPERATURE;

FILTRATION; HUMANS; IMMUNOGLOBULIN G; MOLECULAR WEIGHT; PARVOVIRUS; TEMPERATURE;

PARVOVIRUS;

EID: 78650227630     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.494     Document Type: Article

References (23)

1. Kelley B. Industrialization of mAb production technology. MAbs. 2009; 1: 1-10.
2. Bolton G, Spector S, LaCasse D. Increasing the capacity of parvovirus retentive membranes: the viresolve prefilter. Biotech Appl Biochem. 2006; 43: 55-63.
3. Siwak M, An H, Cormier J, Kinzlmaier D. Process for removing protein aggregates and virus from a protein solution. US Patent 7, 118, 675, February 4, 2003.
4. Ireland T, Bolton G, Noguchi M. Optimizing virus filter performance with prefiltration. BioProcess Int. 2005; 7: 44-47.
5. Maheu D, Rosenthal S, Bogaerts C, Boychyn M, Abraham S. Development and optimization of a parvovirus retention filter for a biological process. National Meeting of the American Chemical Society, Philadelphia, PA, August 2008.
6. Gefroh E, Sedstrom C, Tillotson B, Vedantham G. Parvovirus filters for mAb process platform, National Meeting of the American Chemical Society, San Francisco, CA, September 2006.
7. Bakhshayeshi M, Zydney A. Effect of solution pH on protein transmission and membrane capacity during virus filtration. Biotechnol Bioeng. 2008; 100: 108-117.
8. Bjellqvist B, Basse B, Olsen E, Celis JE. Reference points for comparisons of two-dimensional maps of proteins from different human cell types defined in a pH scale where isoelectric points correlate with polypeptide compositions. Electrophoresis. 1994; 15: 529-539.
9. Ireland T, Lutz H, Siwak M, Bolton G. Viral filtration of plasma-derived human IgG: a case study using Viresolve NFP. BioPharm Int. 2004; 17: 38-44.
10. Bailley M, Felo M, Lin B, Dibella E, Alred P. Planova 15N filter performance and small virus clearance in the mAb1 purification process-a feasibility study. National Meeting of the American Chemical Society, Philadelphia, PA, August 2008.
11. Bolton G, Boesch AW, Lazzara MJ. The effects of flow rate on membrane capacity: development and application of adsorptive membrane fouling models. J Membr Sci. 2006; 279: 625-634.
12. International Conference on Harmonization (ICH). Quality Guideline Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (ICH Q5A), 1998.
13. Parrella J, Wu Y, Kahn D, Genest P. RUNspike, a complementary virus filter spiking method: a solution to the problem of reduced throughput due to the addition of the virus spike, PDA. J Pharm Sci Technol. 2009; 63: 547-558.
14. Khan N, Parrella J, Genest P, Colman M. Filter preconditioning enables representative scaled-down modelling of filter capacity and viral clearance by mitigating the impact of virus spike impurities. Biotechnol Appl Biochem. 2009; 52: 293-301.
15. Genest P, Campbell J, Crump S, Cabatingan M, Miao F. An improved method for virus filter qualification and implementation using flow decay to determine processing endpoint. BioProcess Int. 2006; 2: 2-5.
16. Lute S, Bailey M, Combs J, Sukumar M, Brorson K. Phage passage after extended processing in small-virus retentive filters. Biotechnol Appl Biochem. 2007; 47: 141-151.
17. Lowenstein I. Next Generation Virus Clearance Technologies, ISPE Conference, Tampa, FL, March 2009.
18. Gefroh E, Madrid L, Fisher J, Parrella J, Dehghani H, Vunnum S, Vedantham G. Virus retention validation of parvovirus filters: challenges and solutions, National Meeting of the American Chemical Society, Philadelphia, PA, August 2008.
19. Jones C, Denton A. Integration of large scale chromatography with nanofiltration for an ovine polyclonal product, European Downstream Technology Forum, Goettingen, Germany, May 2007.
20. Marques B, Roush D, Goklen K. Virus filtration of high-concentration monoclonal antibody solutions. Biotechnol Prog. 2009; 25: 483-491.
21. Hongo-Hirasaki T. Robust small virus removal with planova virus-removal filters: no effect from varying virus-spike quality and concentration in a validation model. BioProcess Int. 2007; 5: 74-75.
22. Hongo-Hirasaki T, Yamaguchi K, Yanagida K, Okuyama K. Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova 20N. J Membr Sci. 2006; 278: 3-9.
23. Specht R, Genest P. Alternative virus filter validation strategies: a little extra effort during validation yields a minimum cost of goods for the life of your process, PDA Annual Meeting, Las Vegas, NV, 2009.